Representation of Black men with mHSPC in clinical trials

Multifactorial Causes of Racial Disparities

Clinical Trial Representation

Key Themes:

• Black men are significantly underrepresented in prostate cancer clinical trials (<5% in most studies).
• Many trials fail to provide race-specific data.
• The ARANOTE study achieved 10% representation of Black men.
• Representation is critical for both clinicians and patients to understand treatment applicability.

Key Points for Physicians:

• Consider the racial composition of clinical trials when evaluating evidence.
• Note the stronger evidence base for darolutamide in Black men from ARANOTE.
• Acknowledge limitations in data generalizability when discussing treatment options with patients.

Notable Insights: The 10% representation in ARANOTE, although still below the proportion of Black men in the prostate cancer population, represents a significant improvement over typical enrollment patterns and enables more meaningful subgroup analysis.

Clinical Significance: Improved representation in the ARANOTE study provides a stronger evidence base for treatment decisions in Black men with mHSPC.